Just «a pill». Sixty years of discoveries and achievements which have changed the world. Part II. The innovation of hormonal contraception: the harmony of the composition - the most physiological contraception


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This part of the literature review presents the results of studies in the field of hormonal contraception in real clinical practice. It has been shown that combined oral contraceptive (COC) containing estradiol valerate and dienogest in a four-phase regimen has a lower risk of thromboembolic events compared to other COCs, including levonorgestrel-containing COCs; it is more effective and has a high degree of user satisfaction, including a cohort under 25. It has also been demonstrated that the use of modern COCs reduces the risk of death from any cause, including breast cancer and circulatory diseases.

Full Text

Restricted Access

About the authors

Galina B. Dikke

Academy of Medical Education n.a. F.I. Inozemtsev

Email: galadikke@yandex.ru
Dr. Sci. (Med.), Associate Professor, Professor of the Department of Obstetrics and Gynecology with a course of reproductive medicine

References

  1. Fait T, Buryak D., Cirstoiu M.M., et al. Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs in context. 2018;7:212510. Doi: 10.7573/ dic.212510.
  2. Ahrendt H.J., Makalova D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436-44. Doi: W.1016/j.contraception.2009.03.018.
  3. Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13-24. doi: 10.1016/j.beem.2012.09.004.
  4. Fleikinheimo O. Bitzer J., Garcia Rodriguez L. Real-world research and the role of observational data in the field of gynaecology - a practical review. Eur J Contracept Reprod Health Care. 2017;22(4):250 59. doi: 10.1080/13625187.2017.1361528
  5. Dinger J., Do Minh T., Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328-39. Doi: 0.1016/j.contraception.2016.06.010.
  6. Barnett C, Hagemann C., Dinger J., et al. Fertility and combined oral contraceptives -unintended pregnancies and planned pregnancies following oral contraceptive use - results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2017;22:17-23. doi: 10.1080/13625187.2016.1241991.
  7. Barnett C., Dinger J., Minh T.D., Heinemann K Unintended pregnancy rates differ according to combined oral contraceptive - results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2019; 24(4): 247-50. doi: 10.1080/13625187.2019.1629412.
  8. Briggs P., Serrani M., Vogtlander K. Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dieno-gest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health. 2016;8:477-87. Doi: 10.2147/ IJWH.S107586.
  9. Ahrendt H.J., Makalova D., Parke S., et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):43644. doi: 10.1016/j.contracep-tion.2009.03.018.
  10. Fraser I.S., Parke S., Mellinger U., et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oes-tradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258-69. doi: 10.3109/13625187.2011.591456.
  11. Paoletti A.M., Lello S., Di Carlo C., et al. Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol Endocr. 2016;32(1):61-4. doi: 10.3109/09513590.2015.1079175.
  12. Junge W., Mellinger U., Parke S., Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573-84. doi: 10.2165/11590220-000000000.
  13. Grandi G., Piacenti I., Volpe A., Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol. 2014;30(9):676-80. doi: 10.3109/09513590.2014.922947.
  14. De Leo V., Fruzzetti F., Musacchio M.C., et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88(3):364-68. doi: 10.1016/j.contraception.2012.09.003.
  15. Charlton B.M., Rich-Edwards J.W., Colditz G.A., et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study. BMJ. 2014;349:g6356. doi: 10.1136/bmj.g6356.
  16. Hannaford P.C., Iversen L., Macfarlane T.V., et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010;340:c927. doi: 10.1136/bmj.c927.
  17. Zhong G.C., Cheng J.H., Xu X.L., Wang K. Metaanalysis of oral contraceptive use and risks of all-cause and cause-specific death. Int J Gynaecol Obstet. 2015;131(3):228-33. Doi: 10.1016/j. ijgo.2015.05.026.
  18. Ahmed S., Li Q., Liu L., Tsui A.O. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet. 2012;380:111-25.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies